Safety and immunogenicity of SpikoGen®, an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populationsArticle Published on 2022-09-012022-11-15 Journal: Clinical microbiology and infection : the official [Category] COVID19(2023년), SARS, 진단, [키워드] Advax-CpG adverse event antibody Cellular immune response composed conducted COVID-19 COVID-19 vaccine dose double-blind fatigue geometric mean concentration humoral incidence injection site pain Mild outcome participant phase Phase 2 phase 2 trial Placebo placebo-controlled Population primary immunogenicity Protein Randomized randomized placebo-controlled trial receive Safety safety profile SARS-CoV-2 SARS-CoV-2 spike protein second dose Serious Adverse Event Seroconversion seroconversion rate seronegative seropositive SpikoGen subunit subunit protein vaccine the placebo group vaccination Vaccine Volunteer were recorded [DOI] 10.1016/j.cmi.2022.04.004 PMC 바로가기
The short-term effect of a myofascial protocol versus light touch applied to the cervical spine towards the prevention of balance disorders in the elderly: protocol of a randomised controlled trialArticle Published on 2022-08-312022-10-05 Journal: Chiropractic & manual therapies [Category] SARS, 임상, [키워드] applied balance balance disorder battery Cervical cervical spine concerning Consequences COVID demonstrated double-blind Effect effective elderly evaluator experiment experimental group Gait group Health Inclusion influence Intervention knowledge lower limb lower limbs manual Mobility muscle Myofascial Myofascial release Neck Non-invasive occur Older adults Pain pandemic parameter Patient performance physical physiological Placebo placebo group prevention protection protocol Psychological randomised controlled trial Randomized receive recruitment reduce risk spine strength Strength. subject the placebo group Therapeutic treatment therapy trauma Treatment Variability [DOI] 10.1186/s12998-022-00446-0 PMC 바로가기 [Article Type] Article
A randomized trial of probiotic supplementation in nurses to reduce stress and viral illnessRandomized Controlled Trial Published on 2022-08-302022-10-05 Journal: Scientific Reports [Category] 비임상, 임상, [키워드] animal animal model average circulating Community conducted COVID19 detect Effect environmental factor Evidence Factors Gut gut microbiota highlight Human Immunity ingestion Lactobacillus rhamnosus large trial no significant difference Nurse pandemic participant Participants pathway Perceived stress psychological health public health randomized trial reduce reduced reported symptom Stress stress level Symptom the placebo group trajectory trials viral infection [DOI] 10.1038/s41598-022-19104-9 PMC 바로가기 [Article Type] Randomized Controlled Trial
A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load코로나19 고위험 보행 환자를 대상으로 한 밤라니비맙과 에테세비맙의 무작위 위약 대조 임상 시험 및 지속적으로 높은 바이러스 부하의 예후 가치 검증Randomized Controlled Trial Published on 2022-08-242022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 변종, 임상, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 age ambulatory ambulatory patient ambulatory patients antibody treatment applicability bamlanivimab baseline characterized clinical clinical status Cohort confidence interval coronavirus coronavirus disease Coronavirus disease 2019 correlated COVID-19 COVID-19 test Day death determine etesevimab expand first positive greater high risk Hospitalization infused Interim analyses interim analysis intravenously investigated load lower dose median median age Mild-to-moderate NCT04427501 occurred optimal dose outcome Patient persistently high viral load. phase Placebo placebo group receiving reduction in respiratory risk factor SARS-CoV-2 severe acute respiratory syndrome Coronavirus severe COVID-19 Support the placebo group These data those receiving placebo Treatment Trial validation value variant Viral Viral load [DOI] 10.1093/cid/ciab912 PMC 바로가기 [Article Type] Randomized Controlled Trial
A randomised, double-blind, placebo-controlled, multicentre clinical trial of AZD1656 in diabetic patients hospitalised with COVID-19: The ARCADIA Trial – implications for therapeutic immune modulationResearch article Published on 2022-08-182022-10-05 Journal: EClinicalMedicine [Category] 바이오마커, 변종, 임상, [키워드] 1:1 Activation Adaptive immune response addition adverse event ARCADIA assigned AZD1656 Clinical improvement clinical trial Complete COVID-19 cytokine Czech Republic Day death decrease diabetes diabetic patient diabetic patients dose double-blind duration of hospitalisation Efficacy Excalibur False positive finding Full Analysis Set funding Glucokinase activator group homeostatic hospital hospital discharge hospitalised identify immune Immune cell immune modulation immune response Immunochemistry immunomodulatory effect Immunophenotyping implication indicated Innovation investigated involved less Medicine multicentre nine no difference Patient phase Phase 2 Placebo placebo-controlled placebo-controlled clinical trial primary analysis primary endpoint pro-inflammatory randomised Randomly receive recruited reduction in Registered regulatory T cells required risk Romania SARS-CoV-2 screened statistically significant difference suggested Tablet the placebo group therapeutic therapeutic effect treated Treatment treatment allocation Tregs Trial usual care with COVID-19 [DOI] 10.1016/j.eclinm.2022.101604 [Article Type] Research article
SARS-CoV-2 accelerated clearance using a novel nitric oxide nasal spray (NONS) treatment: A randomized trialArticle Published on 2022-08-012022-10-06 Journal: Lancet Reg Health Southeast Asia [Category] 진단, [키워드] 1:1 95% CI accelerate accelerated age Anti-viral treatment assessment baseline clearance clinical trial Comorbidities comparable Concentration COVID-19 COVID-19 illness defined demonstrated double-blind Endpoint evaluated funding greater greater transmissibility high risk individuals infected with SARS-CoV-2 Laboratory Limited median Mild multicentre mutate nasal Nasal spray nasal swab nitric oxide nostril parallel group Patient pharmaceutical Placebo placebo-controlled polymerase chain primary analysis population progression proportion provided Randomized randomized trial receiving reduce reverse transcription RT-PCR SARS-CoV-2 SARS-CoV-2 RNA secondary Seven study medication symptomatic the placebo group therapy Treatment treatment difference vaccination Viral load virus virus clearance virus RNA [DOI] 10.1016/j.lansea.2022.100036 PMC 바로가기 [Article Type] Article
Noradrenergic Add-on Therapy with Extended-Release Guanfacine in Alzheimer’s Disease (NorAD): study protocol for a randomised clinical trial and COVID-19 amendments알츠하이머병(NorAD)에서 연장 방출 구안파신을 사용한 노르아드레날린성 추가 요법: 무작위 임상 시험 및 COVID-19 수정안에 대한 연구 프로토콜Article Published on 2022-08-012022-09-11 Journal: Trials [Category] 임상, [키워드] activities activity Add-on therapy addition Adrenergic receptor affected Alzheimer's disease Alzheimer’s disease approved assessment Attention attention deficit baseline Brain burden cholinesterase inhibitor clinical trial Cognition cognitive Combination combination therapy COVID-19 Daily daily living determine disease disorder double-blind dysfunction evaluate Evidence executive Follow-up function Guanfacine Guanfacine. hyperactivity IMPROVE include interview inventory involved locus measure Mild mild to moderate moderate modulating Neuropsychiatric NorAD noradrenergic observation outcome participant pathological change pathological changes pathway Pathways Placebo placebo group placebo-controlled Primary outcome randomised receive receptor Regulation secondary Secondary outcomes Study protocol Symptom symptomatic synergistic synergistic effect Test the placebo group thought Treatment treatment group Trial [DOI] 10.1186/s13063-022-06190-3 PMC 바로가기 [Article Type] Article
Safety and immunogenicity of the FINLAY-FR-1A vaccine in COVID-19 convalescent participants: an open-label phase 2a and double-blind, randomised, placebo-controlled, phase 2b, seamless, clinical trialCOVID-19 회복기 참가자에 대한 FINLAY-FR-1A 백신의 안전성 및 면역원성: 공개 라벨 2a상 및 이중 맹검, 무작위 배정, 위약 대조, 2b상, 심리스, 임상 시험Clinical Trial Published on 2022-08-012022-09-11 Journal: The Lancet. Respiratory Medicine [Category] COVID19(2023년), SARS, 변종, 임상, [키워드] 95% CI adverse event All participants Alpha anti-RBD antibody assigned Asymptomatic Beta clinical clinical trial clinical trials Complete control group control groups convalescent convalescent individual convalescent individuals COVID-19 criteria Cuba defined delta variant Delta variants dimeric double-blind education elicited ELISA Endpoint enrolled Environment evaluate evaluated experimental group first stage geometric mean geometric mean titre geometric mean titres greater hematology ICTRP IgG antibodies immune response immunogenicity immunology increase in injected injection injection site Intervention intervention group Mild minor Moderate COVID-19 natural immunity Negative PCR neutralisation test neutralising antibody Occurrence Open-label Pain participant Participants PCR test per-protocol population Phase 1 Phase 2 Placebo placebo group placebo-controlled prevaccination Primary outcome Primary outcomes Public randomised Randomly Receptor binding domain recruited Registered registry reported Safety safety analysis safety population safety profile SARS-CoV-2 Science seamless secondary Secondary endpoints Serious Adverse Event Serious Adverse Events seroconversion rate sexual single dose stages study population technology the placebo group titre Trial two groups vaccination Vaccine vaccine immunogenicity Virus neutralisation Volunteer was done WHO-ICTRP [DOI] 10.1016/S2213-2600(22)00100-X PMC 바로가기 [Article Type] Clinical Trial
Positive Effects of Vitamin D Supplementation in Patients Hospitalized for COVID-19: A Randomized, Double-Blind, Placebo-Controlled TrialRandomized Controlled Trial Published on 2022-07-262022-10-05 Journal: Nutrients [Category] COVID19(2023년), SARS, 임상, [키워드] addition administration calcifediol cholecalciferol circulating Clinical improvement Clinical outcome clinical recovery COVID COVID-19 COVID-19 patient COVID-19 severity Day deficiency demonstrated double blind Effect enrolled Hospital stay Hospitalization Hospitalized Mortality Patient patients per day pilot study Placebo Randomized reduced SARS-CoV-2 SARS-CoV-2 positivity significantly significantly lower still hospitalized subject supplemental oxygen the patient the placebo group the WHO therapy treated Vitamin D Vitamin D status Vitamin D supplementation with COVID-19 [DOI] 10.3390/nu14153048 PMC 바로가기 [Article Type] Randomized Controlled Trial
Estimation of vaccine efficacy for variants that emerge after the placebo group is vaccinated위약군 백신 접종 후 나타나는 변이체에 대한 백신 효능 추정Article Published on 2022-07-202022-09-11 Journal: Statistics in medicine [Category] COVID19(2023년), SARS, 변종, 임상, [키워드] approach assumption clinical trial Cox regression demonstrated develop distribution Effects Efficacy estimation evaluate Follow-up hazard illustration misspecification Observational data Placebo placebo group Poisson proportion proportional hazards model proportions Randomized rare disease reflect SARS-CoV-2 Sensitivity analyses sensitivity analysis sieve analysis strain Strains Surveillance surveillance data the placebo group the vaccine vaccination Vaccine vaccine efficacy vaccine trial variant variants [DOI] 10.1002/sim.9405 PMC 바로가기 [Article Type] Article